Eplontersen Stumbles in Phase 3 ATTR-CM Trial, Setting Ionis Up for a Sharp Stock Decline

summarizeSummary

Ionis Pharmaceuticals announced that the Phase 3 CARDIO-TTRansform trial of eplontersen in ATTR-CM failed to meet its primary endpoint. The drug did not show a statistically significant benefit over placebo in reducing cardiovascular mortality and recurrent events. This is a major pipeline blow for Ionis and partner AstraZeneca.

check_boxKey Events · Product Development and Regulatory · IONS

• Phase 3 Trial Failure

  In the CARDIO-TTRansform trial for ATTR-CM, eplontersen missed the primary composite endpoint of cardiovascular mortality and recurrent cardiovascular events.

• Subgroup Analysis Shows Mixed Results

  A prespecified subgroup of patients on eplontersen monotherapy showed a nominally significant hazard ratio of 0.71, but no benefit was observed in those receiving background stabilizer therapy.

• Impact on Pipeline and Valuation

  ATTR-CM represented a major growth opportunity; this failure removes a key near-term catalyst and increases reliance on wholly owned assets like TRYNGOLZA.

• Next Steps

  Full data will be presented at the ESC Congress in August 2026. Ionis and AstraZeneca will continue to analyze the dataset.

auto_awesomeAnalysis · IONS · Life Sciences

A major setback for Ionis: the CARDIO-TTRansform Phase 3 trial of eplontersen, a key asset partnered with AstraZeneca, missed its primary endpoint in ATTR-CM. The failure erases a large market opportunity and removes a significant growth driver, likely pressuring the stock—especially against a backdrop of recent insider selling and elevated expectations fueled by positive pipeline news. Going forward, Ionis will lean more heavily on its wholly owned portfolio, including the recently launched TRYNGOLZA, to reach its 2028 cash flow breakeven target.